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General Principles for the Validation of 
Proarrhythmia Risk Prediction Models: 
An Extension of the CiPA In Silico Strategy
Zhihua Li1,*, Gary R. Mirams2, Takashi Yoshinaga3, Bradley J. Ridder1, Xiaomei Han1, Janell E. Chen4, 
Norman L. Stockbridge5, Todd A. Wisialowski6, Bruce Damiano7, Stefano Severi8, Pierre Morissette9,  
Peter R. Kowey10, Mark Holbrook11, Godfrey Smith12,13, Randall L. Rasmusson14, Michael Liu15,  
Zhen Song15, Zhilin Qu15, Derek J. Leishman16, Jill Steidl-Nichols17, Blanca Rodriguez18,  
Alfonso Bueno-Orovio19, Xin Zhou20, Elisa Passini18, Andrew G. Edwards19, Stefano Morotti19,  
Haibo Ni19, Eleonora Grandi19, Colleen E. Clancy19, Jamie Vandenberg20,21, Adam Hill20,21,  
Mikiko Nakamura22, Thomas Singer23, Liudmila Polonchuk23, Andrea Greiter-Wilke23, Ken Wang23, 
Stephane Nave24, Aaron Fullerton25, Eric A. Sobie26, Michelangelo Paci27, Flora Musuamba Tshinanu28,29 
and David G. Strauss1
This white paper presents principles for validating proarrhythmia risk prediction models for regulatory use as discussed 
at the In Silico Breakout Session of a Cardiac Safety Research Consortium/Health and Environmental Sciences Institute/
US Food and Drug Administration–sponsored Think Tank Meeting on May 22, 2018. The meeting was convened to 
evaluate the progress in the development of a new cardiac safety paradigm, the Comprehensive in Vitro Proarrhythmia 
Assay (CiPA). The opinions regarding these principles reflect the collective views of those who participated in the 
discussion of this topic both at and after the breakout session. Although primarily discussed in the context of in silico 
models, these principles describe the interface between experimental input and model-based interpretation and are 
intended to be general enough to be applied to other types of nonclinical models for proarrhythmia assessment. This 
document was developed with the intention of providing a foundation for more consistency and harmonization in 
developing and validating different models for proarrhythmia risk prediction using the example of the CiPA paradigm.
In July 2013, a Think Tank jointly sponsored by Cardiac Safety 
Research Consortium (CSRC), Health and Environmental 
Sciences Institute (HESI), and the US Food and Drug 
Administration (FDA) proposed a new cardiac safety paradigm, 
Comprehensive in Vitro Proarrhythmia Assay (CiPA). CiPA uses 
a new mechanistic, model-informed approach to predict the risk 
of Torsade de Pointes (TdP), a rare but potentially lethal form of 
ventricular tachycardia that can be induced by drugs and lead to 
sudden death.1 Since its inception, global stakeholders includ-
ing regulatory agencies (the FDA, European Medicines Agency, 
Health Canada, and the Japan Pharmaceuticals and Medical 
Devices Agency), industry, and academia have assembled various 
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working groups under a joint effort, the CiPA Initiative, to drive 
forward different components of CiPA.2–4 Relevant to this white 
paper, the In Silico Working Group (ISWG) has developed5–8 
and validated9 an in silico cardiomyocyte model that can be used 
as part of an integrated TdP risk prediction tool under the new 
CiPA paradigm.
To evaluate the progress of the CiPA Initiative, CSRC/HESI/
FDA sponsored another Think Tank meeting in Washington, DC 
on May 21, 2018,10 which was followed by a series of breakout ses-
sions for in-depth discussion of various components of CiPA. This 
white paper presents the outcome of the In Silico Breakout Session, 
which primarily focused on establishing a set of general principles 
to qualify models/metrics to be used for proarrhythmia risk predic-
tion using the example of the CiPA paradigm. Although discussed 
in the context of using in silico models to predict TdP risk, the ge-
neric nature of these principles makes it possible to apply them to 
any type of nonclinical models (in silico, in vitro, ex vivo, and in 
vivo) for the risk assessment of TdP and other types of arrhythmias. 
Parallel to the ongoing Q&A development process to modify the 
current International Council for Harmonisation (ICH) cardiac 
safety regulatory guidelines,11 the development of this document is 
intended to provide a starting list of consideration points for stake-
holders to evaluate and compare different and newer proarrhyth-
mia risk prediction models to subsequently aid in decision making.
BACKGROUND
The CiPA paradigm was proposed to address the lack of spec-
ificity of the current cardiac safety paradigm that relies on sur-
rogate markers of in vitro hERG block and in vivo/clinical QTc 
prolongation,1 which are stipulated by the ICH S7B12 and E14 
guidelines,13 respectively. Although highly successful in prevent-
ing new drugs with potential TdP risk from entering the market, 
the current paradigm is considered to have low positive predictive 
value10 and may have unduly constrained drug development.2 In 
recognition of these limitations, the industry and scientific com-
munity have developed and characterized a plethora of additional 
assays (in vitro patch clamp assays on other ion channels,14 in-
duced pluripotent stem cells (iPS)-derived cardiomyocytes,15 in 
silico model-based assays,16 etc.) with the aim of improving our un-
derstanding and management of proarrhythmia risk. The CiPA 
Initiative represents a community-wide effort to develop such an 
assay by taking a focused, systematic, and mechanistic approach to 
integrate various components. Under CiPA, the assessment of TdP 
risk for new drugs will be based primarily on mechanistic in silico 
cardiac electrophysiology models parameterized by in vitro mea-
surements of drug effects on various cardiac ion channels, with a 
check of additional effects that may be missed by in vitro/in silico 
assays using integrated biological systems (human electrocardiog-
raphy and stem-cell-derived cardiac myocytes).2 Because the in-
tended use of in silico proarrhythmia risk prediction models under 
CiPA is aiding regulatory decision making, a rigorous approach 
to strictly separate model training from validation is preferred,17 
as discussed in regulatory guidelines about biomarker qualifica-
tion.18 Of note, the term "validation" is intended here as the evalu-
ation of “how good is the model for a given prediction task” rather 
than of “how good is it as a representation of the real physiological 
system,” although the latter is also important for model develop-
ment (see Principle 5 below). The term proarrhythmia risk predic-
tion model in this document refers to the entire prediction system 
that includes the underlying platform to mimic the response of a 
physiological system (could be in silico models or in vitro/in vivo/ex 
vivo experimental models) as well as the associated prediction met-
rics and scoring algorithms for risk assessment.
The CiPA Steering Committee proposed2 a development pipe-
line with a step-wise approach that includes model training using 
a set of 12 training drugs, model freezing with prespecified perfor-
mance measures and acceptable levels, and finally model validation 
using a dedicated set of 16 validation drugs (see ref. 19 for a review 
of this strategy). It is envisioned that a similar prospective design 
could serve as the general framework for qualifying any nonclin-
ical models (in vitro, in silico, ex vivo, in vivo) for proarrhythmia 
risk prediction. However, a set of principles needs to be established 
to ensure that different models subjected to this validation frame-
work are evaluated in a consistent manner.
Principles for validating specific types of computational mod-
els have been established and adopted by international regulatory 
guidelines in other areas. In 2004 a set of principles for the val-
idation of (quantitative) structure–activity relationship (QSAR) 
models for regulatory purposes was established by the Organization 
for Economic Co-operation and Development (OECD), an inter-
governmental organization to coordinate and harmonize policies 
across member countries.20 These principles were later fully ad-
opted by ICH guideline M7(R1) to evaluate the acceptability of 
QSAR models for the regulatory assessment of mutagenic impu-
rities in pharmaceuticals.21 Although OECD principles were spe-
cifically developed for QSAR models, they provide a conceptual 
framework that can be generalized to other types of risk prediction 
models. In addition, the ICH S7B/E14 Q&A Concept Paper11 
proposes two separate sets of Q&As for S7B: one about experimen-
tal protocol standardization and best practice/data quality consid-
erations using various assays (voltage patch clamp, in vitro human 
myocytes, etc.) at the data collection phase, while the other about 
general principles for proarrhythmia models, which mainly regards 
evaluating the model’s ability to interpret the data and perform risk 
prediction. Such a conceptual separation makes it possible to dis-
cuss generic rules of evaluating the predictivity of risk prediction 
models without specifying the underlying assays for data collection 
and type of collected data. Since the OECD principles provide a 
prototype for such generic rules, the principles discussed at the In 
Silico Breakout Session of the CiPA Meeting were primarily based 
on the OECD principles, with the context realigned with the pur-
pose of proarrhythmia risk assessment. This new set of CiPA prin-
ciples are discussed in the following Basic Principles section.
BASIC PRINCIPLES
Principle 1: A defined end point consistent with the context 
of use
This principle is modified from OECD principle 1,20 with the 
added emphasis that the end points of model predictions should 
be consistent with the “context of use” (CoU). The end point 
of a proarrhythmia risk prediction model defines what type of 
(proarrhythmia) risk it predicts, and the CoU defines the role 
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and scope of a model in addressing specific questions or mak-
ing specific decisions.22 For example, if the defined end point is 
the risk of drug-induced TdP, then one possible CoU could be 
to use the model prediction as part of an integrated risk assess-
ment to determine appropriate language in the drug label about 
its TdP risk.11 Such an end point needs to be defined using a 
clinical risk categorization system (a set of drugs with known 
clinical TdP risk liabilities and known clinical exposure levels).1 
It is possible to use other types of risk as model end points. For 
instance, QT prolongation is an end point closely related to but 
distinct from TdP, despite the fact that some clinical categori-
zation systems mix these two end points.23 Models designed to 
predict the risk of QT prolongation should have the end point 
defined by a series of drugs’ clinical QT information, such as 
Gintant et al.24 categorization system of QT positive vs. QT 
negative drugs based on Thorough QT studies. In addition, 
in  silico models have been developed to simulate various types 
of proarrhythmia, including ventricular tachycardia.25,26 Once 
appropriate clinical risk categorization systems are established, 
these end points can be used by the in silico models to predict 
the risk of different types of drug-induced proarrhythmia.
Numerous clinical TdP risk categorization systems exist in the 
literature. For example, Redfern et al.27 developed a five-class TdP 
risk categorization system that is widely used, and subsequently 
updated/expanded by various groups.28–30 Arizona Center for 
Education and Research (AZCERT) maintains Web-based lists 
of drugs that are categorized into classes with known, possible, or 
conditional risk of QT prolongation and/or TdP.23 Primarily based 
on these databases, a number of two-class categorization systems 
(TdP+  and TdP−) have also been proposed.31,32 To address lim-
itations from some of the above systems (e.g., a mixture of QTc 
prolongation risk with TdP risk creating a mismatch between end 
points and CoU), the CiPA Initiative organized a team of expert 
clinicians, safety pharmacologists, and cardiac electrophysiologists 
to develop a dedicated CiPA system where 28 drugs were catego-
rized into high, intermediate, and low risk of TdP based on public 
literature, the FDA adverse event reporting system (AERS) data-
base, and expert opinion.2 It is generally recognized that true risk 
levels are likely to be on a continuous scale rather than discrete.33 
At present it is difficult to define such a continuum of clinical TdP 
risk for reference drugs due to the lack of reliable quantification 
of each drug’s risk level. The CiPA three-class system represents a 
compromise between quantitative and qualitative risk assessment 
by classifying reference drugs discretely into ranked risk levels 
(High  >  Intermediate  >  Low). Regulatory decision making de-
pends on benefit–risk assessment.34 A more fine-grained risk clas-
sification (such as the classification of High vs. Intermediate risk 
instead of a single High risk category), although not as informative 
as a continuous risk quantification system, might help to distin-
guish drugs with similar benefit profiles but different benefit–risk 
ratios. For instance, if two drugs have different risk levels (one high 
and one intermediate risk) but similar benefit (the same indications 
with comparable efficacy), then the one classified as intermediate 
risk could be a better opportunity for development compared with 
the high risk one. On the other hand, if two drugs have the same 
risk levels (both intermediate) but different benefit (one with less 
dangerous alternative and one without), then the one with readily 
available alternatives might be treated with more caution. As an ex-
treme example, astemizole and some other intermediate risk drugs 
were removed from the market due to such considerations.35
Because of the rarity of TdP and complex confounding factors 
like comorbidity and comedication, at present there is no consen-
sus clinical TdP risk categorization system, and many models were 
developed using different TdP risk categorization systems with 
different drug sets and sometimes contradicting risk level assign-
ments.36 Ideally, a progressive harmonization of existing TdP risk 
categorization systems should take place that undergoes a public 
and transparent process to generate a large set of drugs with con-
sensus clinical risk categories. At present, individual stakeholders 
should evaluate existing clinical proarrhythmia risk categoriza-
tion systems, such as the CiPA categories for TdP risk, and decide 
on the best calibration system that fits the specific purpose.
Principle 2: An unambiguous algorithm
This principle is the same as OECD Principle 2.20 Predicting clin-
ical proarrhythmic risk using a model-informed approach is a mul-
tistep process that involves a series of individual algorithms. For 
example, some published in silico cardiac models for TdP risk pre-
diction usually include a cardiac cellular model to reconstruct elec-
trophysiology,16,37,38 a pharmacological component to translate in 
vitro ion channel block data into pharmacological parameters (ei-
ther half inhibitory concentrations (IC50s) or dynamic drug bind-
ing parameters,7) and a specific simulation protocol to compute 
predictive TdP risk metric(s), such as APD90,29 qNet,9 APD50 
plus diastolic calcium,32 repolarization abnormalities,39–42 or 
threshold concentration to cause TdP.43,44 In addition, there are 
also studies where in vitro ion channel data were directly input 
into simpler statistical models to derive a TdP risk metric.31,45,46 
Finally, even in vitro and in vivo/ex vivo experimental models, such 
as the iPS cell-derived cardiomyocyte (iPS-CM) assays developed 
by Japan iPS Cardiac Safety Assessment (JiCSA),15,47 and canine 
Purkinje fiber models,30 require computational algorithms to inte-
grate various electrophysiological measurements into a compound 
scoring system for TdP risk prediction. For example, the JiCSA 
study evaluated two algorithms for risk classification. In the first 
algorithm, a TdP risk score based on the maximum changes of 
field potential duration induced by drugs in the iPS-CM assay 
is combined with a margin value (the ratio of human free thera-
peutic plasma concentration to the free concentration in culture 
medium at which an arrhythmia event was observed) to form a 
two-dimensional map to classify drugs into three risk categories.15 
In the second algorithm, a logistic regression model developed 
by the CiPA international multisite iPS-CM study48 was applied 
to the JiCSA data set,49 which combines the type of arrhythmia 
event at any concentration, the maximum repolarization change 
at any concentration, and the amount of repolarization change at 
maximum free therapeutic concentration induced by a drug on 
iPS-CM assays to perform risk classification. Although different 
in format (a decision tree based on visual separation vs. a statistical 
model), both are clear and transparent algorithms to integrate and 
interpret underlying electrophysiological measurements for risk 
classification.
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It is expected that all models to be used under CiPA will need to 
have their algorithms and both training and validation data fully 
disclosed, to ensure transparency and enable the users and other 
interested parties to reproduce the results during model develop-
ment and reevaluate the model performance.
Principle 3: A defined domain of applicability
This principle is essentially the same as OECD Principle 3,20 with 
the underlying concepts redefined to fit the purpose of evaluat-
ing models that integrate experimental data for risk prediction. A 
domain of applicability defines the scope and limitations of a model 
based on the information contained in the development (training 
and validation) data sets, and a given model can only be expected 
to make reliable predictions within the applicability domain, or 
in a “similar” situation to the development data set. Since a model 
under CiPA utilizes experimentally derived pharmacological ef-
fects for risk prediction, its applicability domain is defined by the 
experimental procedures applied to, as well as pharmacodynamic 
effects associated with, the drugs during model development.
This principle has several implications. The first one is that 
during the model development stage, all drugs should be tested 
with the same experimental protocol to establish a uniformly de-
fined applicability domain. Note that these protocols can differ for 
different ion channels, but each drug will need to be tested under 
the same experimental conditions for the same channel. This is es-
pecially important because estimates of drug potency (e.g., IC50) 
are highly dependent on the patch clamp experimental methods 
used, and differences in voltage protocols, temperatures, ion chan-
nel expression systems, and quality control standards can lead to 
very different potency estimates across laboratories.9,50–54 The sec-
ond implication is that data used for any new compound predic-
tions by a given model will need to be generated using the same 
experimental protocols as those used for the model training and 
validation compounds. Otherwise, the new drug may be outside of 
the applicability domain of the model, and thus reliability of pre-
dictions cannot be established.
Another implication for this principle is that any proarrhythmia 
risk prediction model can only cover a limited number of proar-
rhythmic mechanisms, which also define the applicability domain 
of the model. A prediction could be unreliable even when the new 
drug follows the same experimental and analytical processes as 
those during model development, when the new drug has a proar-
rhythmic mechanism not considered by the proposed model, for 
instance effects on the beta-adrenergic system, hERG trafficking, 
phosphoinositide 3-kinase pathway,55 or blocking effects on ion 
channels not included in the experimental assay. While some of the 
mechanisms are related to direct ion channel blocking, others are 
related to long-term effects that may not have been well studied. 
Such “missing” effects are intended to be captured by other compo-
nents of CiPA (e.g., stem cell and/or human electrocardiography) 
and, if necessary, to help further develop the model and expand its 
applicability domain.
A special case about changed applicability domain due to 
changed pharmacodynamics is that in silico models simulating 
drug actions on normal human cardiomyocytes could be modified 
to simulate drug actions on specific patient populations or disease 
situations. Such domain expansion could be achieved through two 
approaches:56 (i) create an ensemble of models with different pa-
rameter sets to represent a population of “virtual patients” with 
varying electrophysiological parameters such as ion currents con-
ductance;57–59 and (ii) re-fit (adjusting the parameters and/or struc-
ture of ) the baseline model to represent a specific clinical situation, 
such as long QT syndromes.60–63 These are useful methods that 
may enable risk assessment at the subpopulation or even individ-
ual patient level. However, to validate such predictions, reliable end 
points (clinical risk categorization) would need to be available for 
such subpopulations (please see Principle 1 above and Principle 4 
below). In addition, appropriate CoU would need to be established 
to use these models on specific subpopulations (Principle 1).
Other than different proarrhythmic mechanisms/pharmacody-
namics, the most common cause for drugs falling outside of the 
applicability domain, despite use of the same experimental proce-
dures, comes from lab-to-lab variabilities. These variabilities may 
stem from subtle experimental factors that are hard to standardize 
across labs, e.g., cell lines and culture conditions; or they could be 
due to inherent randomness and intrinsic variability during experi-
mental recordings.51,64,65 Under CiPA, an effort is ongoing to stan-
dardize not only experimental protocols but also quality control 
criteria across labs, with the aim of reducing lab-to-lab variabili-
ties in generating ion channel pharmacology data. Before such a 
standard is fully developed and implemented, due to variability in 
ion channel pharmacology data obtained across labs, it will be nec-
essary for each lab to establish its own applicability domain for a 
given model. To reduce redundant work, it is recommended that, 
after a proarrhythmia model has gone through the training and 
validation stages using all the compounds in the development set, 
a strategy could be established for each model to select a subset 
of “calibration” drugs. This set of drugs would allow each individ-
ual laboratory to check the ability of its internal experimental sys-
tems to generate data to inform the model for risk stratification. 
After performing this lab-specific validation step, each lab could 
use this calibration set to establish the classification thresholds tai-
lored to its own data (lab-specific calibration). Subsequently the 
lab can submit new drug data, along with newly generated data 
from control compounds (a predefined and even smaller subset 
from the “calibration” drugs to assess the consistency between new 
and historical data), and perform risk predictions based upon its 
own self-consistent classification thresholds. Because the purpose 
of the control compounds is to assess experimental reproducibility 
in each submission rather than revalidate or recalibrate the model, 
the number of assays needed for control compounds can be sig-
nificantly lower than those for “calibration” drugs. As an example, 
proarrhythmia risk prediction models that use multi-ion channel 
(for instance hERG, Cav1.2, Nav1.5 peak and late) in vitro data as 
input may select a number (for instance 8) of drugs as “calibration 
set.” A lab that wants to use such a model will need to perform 32 
ion channel assays (eight drugs  ×  four currents) on the “calibra-
tion set” to establish this lab’s own classification thresholds. Such 
lab-specific validation and calibration is typically performed just 
once, or repeated only as needed, for each lab. Subsequently for 
each new drug submission, the lab will need to test one control 
compound on each specific current, with a total of four control 
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assays (one drug × four currents), to establish reproducibility. The 
designation of calibration and control compounds, as well as the 
criteria of a successful lab-specific validation, is specific to each 
proarrhythmia risk prediction model and should be part of the 
model development plan. Since each lab’s new drug will be com-
pared with its own historical data (and classification thresholds), 
the impact of lab-to-lab variability could be minimized.
Principle 4: A stringent strategy and predefined criteria to 
assess predictivity
This principle is conceptually similar to OECD Principle 4,20 but 
reworded to shift the focus from the careful selection of appropriate 
statistical methodologies to the stringent design of the validation 
study. This is because, unlike QSAR models, which are primarily 
reductionist models relying on selected statistical methods to find 
patterns from large data sets, CiPA models are usually mechanistic 
in nature (see Principle 5 below) with extensive information about 
the underlying biological/pharmacological processes but limited 
training and validation drug data sets. Thus, the reliability of a par-
ticular proarrhythmia risk prediction model lies in the stringency 
of the design of the validation strategy to assess predictivity.
This consideration prompted the design of a prospective study 
for the development of TdP risk prediction models by the CiPA 
Steering Committee.1,2 The 28 drugs in the CiPA development set 
were divided into a training set of 12 and a validation set of 16 
compounds, both sets with a diverse distribution of TdP risk cat-
egories, drug classes, and electrophysiological characteristics. The 
calibration of the model and selection of the metric (model train-
ing) should be done based on previously published cardiomyocyte 
data and newly acquired pharmacology data for the 12 training 
drugs before the collection of in vitro data for the 16 validation 
drugs. Prior to the validation study, the model, metric, classifica-
tion thresholds, as well as targeted performance levels, are all to 
be predetermined (“frozen”) based on training data and reported 
either through publications or time-stamped prevalidation docu-
ments. Such a rigorous design ensures an objective assessment of 
the predictivity of the model. Of note, such an assessment of pre-
dictivity is within specific proarrhythmic mechanisms as defined 
by the applicability domain of each model (see Principle 3 for de-
tails). And the rigor needed for predictivity assessment, reflected as 
the stringency of predefined acceptable performance criteria, can 
be determined based on an analysis of the impact and possible con-
sequences of applying the model within its CoU.22
This training-validation strategy is different from the cross val-
idation (e.g., leave-one-out-cross-validation) method commonly 
used to validate TdP prediction models.29,31,32 This is because a 
“hidden” validation data set, where the experimental data were not 
even collected for the validation drugs during the model training 
stage, provides the highest confidence that the model building and 
metric selection process cannot use any information from the vali-
dation data set. At least one model (CiPAORdv1.0) followed this 
step-wise process of selecting the base model,66 further calibrat-
ing the model and screening for the TdP metric based on training 
data,5–7 and successfully passed the validation stage,9 suggesting 
that this prospective design is feasible and can be used to validate 
proarrhythmia risk prediction models.
A strict separation of the 28 CiPA drugs into a training and 
a validation set was maintained during the development of 
CiPAORdv1.0,9 not least by not measuring all validation data 
until training was complete. Such stringency is lost for future mod-
els now that all 28 drugs’ in vitro assessment is finished and data 
were released into the public domain. Any new models to be de-
veloped for TdP risk prediction may need an alternative validation 
strategy that uses a prospective design. It may be beneficial to apply 
the CiPA categorization system to additional compounds to get a 
new list of drugs with clinical TdP risk levels. This new list could 
be kept from the public and used as a “hidden” validation set to 
evaluate the performance of new models proposed to be used for 
regulatory assessment of TdP risk.
A model that successfully went through this training-valida-
tion process is not “frozen” forever. It can still go through further 
rounds of external validation for the users to understand the lim-
itations and/or gain more confidence of the model. It will also 
likely have further incremental changes through continued model 
development after the validation step. Whether or not such further 
development needs a repeat of the full training-validation process 
depends on the nature of the changes. For example, changes to 
computational methods designed to speed calculations of a vali-
dated in silico model might only need to show that they provide the 
same outputs (given the same inputs) as the computational module 
they are designed to replace and repeat a global evaluation using 
the old development data set. On the other hand, if a change is 
applied to an experimental protocol associated with the validated 
model, then new experimental data may need to be generated for 
all drugs in the development data set to repeat the training-valida-
tion process. The requirements to maintain the “validated” status 
of a model after making incremental changes may need to be eval-
uated on a case-by-case basis.
Principle 5: A mechanistic interpretation
This principle is the same as OECD Principle 5, with the phrase 
“if possible” removed to emphasize the importance of mechanistic 
interpretation for CiPA models. Although the term mechanism 
could be used to refer to both the mechanism of action of a drug 
(e.g., specific drug-channel interactions that lead to the pharma-
cological effects), and the mechanism of arrhythmia (e.g., reentry 
mechanism), this principle focuses on the first aspect of the term 
and emphasizes that the model/metric needs to shed light on spe-
cific ion channel/biological pathways through which a drug can 
trigger arrhythmia. As an example, there are two main types of 
in silico models in the literature for TdP risk prediction. One type 
(such as CiPAORdv1.05) simulates the drug effects on computa-
tional models of action potentials at cellular, tissue, or organ levels 
and outputs a metric related to drug-induced changes in repolar-
ization to indicate TdP risk.29,32,39,42,43,61,67 The second type uses 
statistical models/machine learning approaches to directly link in 
vitro drug block measurements (IC50, etc.) to the final TdP risk 
levels.31,45,46 Although differing in complexity, the published ap-
proaches for both types of models have taken into consideration 
the pharmacological effects on the two opposing classes of cardiac 
ion currents (inward and outward currents) that shape the repo-
larization of action potentials and thus provide some mechanistic 
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insight into drug-induced TdP. We consider that all the references 
above do include a mechanistic interpretation (e.g., in even the 
simplest models cited above, the balance of block of inward and 
outward currents is an integral part of the approach) and could 
be used at different stages of drug development. But those ma-
chine-learning algorithms that blindly screened large quantities of 
measured experimental features, without providing links between 
ion channels/pathways targeted by the drug and potential arrhyth-
mic influences, would not deliver a mechanistic interpretation.
In addition to providing an explanation of the clinical risk catego-
rization, mechanistic predictions from models add another layer to 
the validation procedure. Even though the terms “validation” and 
“mechanism” defined in this document focus on clinical risk pre-
dictivity and pharmacology actions, a model needs to represent the 
fundamentals of the underlying physiological system for a credible 
prediction. In line with the OECD guidance on QSAR models,68 
any effort in the validation process to show that a model is consistent 
with existing knowledge of fundamental biological/pharmacological 
processes adds to its credibility and provides scientific support for 
more credible extrapolations than a pure statistical/machine-learning 
 approach.69 This is essentially true since some of the biological pro-
cesses have been shown to be important for the mechanisms of proar-
rhythmia through sensitivity analysis.70,71 Therefore, the ability of a 
model to predict a diverse series of data from experiments designed to 
probe different aspects of the mechanisms underlying proarrhythmia, 
e.g., time-dependent changes of hERG currents after drug applica-
tion, dose response of ion channel block, action potential morphol-
ogy, can be used to assess the confidence in different models, or guide 
the further development of existing models,60 even if these models 
have seemingly similar performance in terms of predicting clinical 
proarrhythmia risk levels in the validation data set.
Principle 6: Appropriate uncertainty quantification
This principle is not part of OECD Principles and has been added 
to CiPA Principles to reflect the need to account for uncertainty 
and variability to make informed decisions using quantitative 
models. CiPA models rely on experimentally derived pharmaco-
logical parameters as model input to predict clinical proarrhyth-
mia risk, but this process has many sources of uncertainty. These 
uncertainties will need to be captured and “propagated” through 
the model to quantify the uncertainty in model prediction,64,72 
which could alter the predicted risk class of a drug. For example, 
Lazic et al.73 proposed an illustrative example of using a Bayesian 
model to predict a drug’s QT prolongation risk based on hERG 
block potency and clinical exposure. In this model various un-
certainties were built into and propagated through the model to 
predict the probability of a compound falling into either the “QT 
prolongation” or “non-QT prolongation” class, rather than predict 
definite binary classification without uncertainty.
One of the major sources of uncertainty is experimental 
variability in the measurement of pharmacological effects. 
Real-world experiments unavoidably exhibit variability,74 and 
in this field, often substantially—by which we mean to a level 
that can markedly affect a subsequent risk prediction. Because 
pharmacological parameters (e.g., IC50s) are derived (fitted) 
from observed data (e.g., dose–response curves), uncertainty 
quantification typically starts by establishing a distribution of 
parameters that could have given rise to the experimental data 
(uncertainty characterization).64,72 These probabilistic distri-
butions are then used as model inputs to translate experimental 
variability into uncertainty of the model output (risk predic-
tion).5 Although a large uncertainty in model inputs does not 
necessarily translate to a large uncertainty in the output due to 
their complex nonlinear relationship,5 we need to quantify this 
uncertainty to reflect our confidence in both experimental mea-
surements and risk assessment. The concept and quantification 
strategy for experimental uncertainty in pharmacological mea-
surements applies to any kind of model (in silico, in vitro, ex vivo, 
and in vivo) for proarrhythmia risk prediction.
Another important source of uncertainty is interindividual 
variability (due to age, gender, ethnicity, etc.) in the subjects to 
whom drugs are administered in the real world, which leads to 
variability in the effects that the very same plasma drug concen-
tration can have on each subject. This can be treated as variability 
in the physiological parameters of those in silico models that sim-
ulate action potentials (as, for example, in ref. 39). While some of 
these parameters are directly measurable, most of them have to be 
indirectly inferred from experimental data,65 similar to pharma-
cological parameters. Thus, the probabilistic distribution method 
mentioned above could in theory be applied as well. However, 
the sheer number of parameters (tens to hundreds of physiolog-
ical parameters vs. typically 2–5 pharmacological parameters), 
and potentially complex covariance structure56 may require the 
development of novel methods to deal with such variability.65 
Similar methods are being developed in other areas (such as phys-
iologically-based pharmacokinetic modeling/PBPK) for realistic 
characterization of population variability in a probabilistic frame-
work.75 In addition, there are many other sources of uncertainty, 
such as the uncertainty in model structures as well as numerical 
precision.74 Typically, there is a tradeoff between biological plau-
sibility (including more sources of uncertainty to reflect reality) 
and model parsimony (using a less complex model).
Note that any sources of uncertainty a model intends to include 
must be defined clearly as part of the algorithm (Principle 2) and 
be included in the training and validation processes (Principle 4). 
Of all the different sources of uncertainty, at a minimum, models 
should characterize and quantify the uncertainty from experimen-
tal variability in measurements of pharmacological effects, as such 
variability captures the uncertainty in measuring a drug’s inherent 
pharmacological properties (such as IC50s in ion channel assays, 
drug-induced arrhythmia events in iPS cell-derived cardiomyocyte 
assays48, and drug-induced action potential changes in isolated 
Purkinje fibre assays30) and forms drug-specific inputs to any kind 
of proarrhythmia risk prediction models (in silico, in vitro, ex vivo, 
or in vivo).
SUMMARY AND RECOMMENDATIONS
This white paper presents a series of general principles for the val-
idation of proarrhythmia risk prediction models illustrated by the 
CiPA paradigm. These principles can be briefly summarized as 
follows as well as in Figure 1, with detailed explanation and con-
sideration elaborated in the Basic Principles section above.
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Generally, a proarrhythmia risk prediction model should have:
1. A defined end point consistent with the context of use, such 
as the CiPA three-class TdP risk categories, or a progressive 
harmonization of existing TdP risk categories with an ex-
panded list of reference drugs
2. An unambiguous algorithm, allowing users to reproduce the 
model development process using associated training and vali-
dation data sets and reevaluate the performance
3. A defined domain of applicability, where all drugs are tested 
using standard experimental procedures and have defined 
pharmacodynamics of proarrhythmic mechanisms, with a 
strategy to establish a lab-specific applicability domain by per-
forming lab-specific validation and calibration
4. A stringent strategy and predefined criteria to assess predictiv-
ity, with a prospective design and step-by-step documentation 
to strictly separate training from validation
5. A mechanistic interpretation of the proarrhythmia risk marker
6. Appropriate uncertainty quantification, at a minimum charac-
terizing and quantifying the uncertainty in the experimentally 
measured pharmacological effects that are drug-specific inputs 
into the models
During the discussion of these principles, a number of future 
directions were identified as important to develop more accurate 
risk prediction models for regulatory assessment of proarrhythmia 
liability. These future directions with high priority include:
1. To harmonize existing clinical risk categorization systems for 
individual proarrhythmia end points (such as TdP) by gener-
ating a large set of drugs with consensus risk quantification 
(either discrete categories or, more preferably, a continuous 
spectrum of risk). Specifically, for the end point of TdP risk, 
although the 28 drugs currently selected by CiPA is a much 
larger number than was used to support the establishment 
of the current ICH S7B/E14 guidelines, it is acknowledged 
Figure 1 A generic flowchart of proarrhythmia risk prediction model development process. Different principles are applied to different steps 
along the model development process. In the first step, a defined end point (type of proarrhythmia risk) consistent with the context of use 
(Principle 1) is chosen. This is enabled by testing a list of drugs based on a defined clinical risk categorization or quantification system. The 
drug list is split into a training set and a validation set. The training set undergoes some defined pharmacological experimental protocols 
to generate experimental data as model input (Principle 3). The experimental variability in the pharmacological assessment needs to be 
captured and propagated through the model via uncertainty quantification (Principle 6). In the meantime, a platform to mimic the response of 
physiological system is chosen. Such platforms can be, for example, induced pluripotent stem cell-derived cardiomyocytes (iPS-CMs), in vivo 
animals, ex vivo tissues, or in silico cardiomyocyte models. Such platforms may be subjected to a development process, for instance to adjust 
the structure and parameters of an in silico model to better replicate cardiac electrophysiology, or to induce the differentiation of iPS cells 
to achieve a more mature phenotype. It is important to characterize the model to determine what proarrhythmic mechanisms such a model 
can cover (Principle 3). The pharmacology data for training drugs can be applied to the developed model to perform model training. Note that 
sometimes the pharmacology assays are performed directly on the platform (such as iPS-CM assays), while for other assays these two are 
separated (such as ion channel data collected by dedicated in vitro assays and then applied to an in silico model). Either way, data generated 
from pharmacology assays will be translated through the model using a defined scoring algorithm (Principle 2) to generate a proarrhythmia 
metric that explains the mechanisms of action of the drug to trigger arrythmia (Principle 5). After the training step the model and targeted 
performance criteria are to be prespecified (Principle 4), and then the validation drugs are tested in the same pharmacology assays to 
generate data for validation. Note that only key steps are shown. Some other aspects, such as continued model development, are left out of 
this figure for visual clarity.
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that there is a need for larger data sets. The hope is now 
that with a progressive harmonization of existing TdP risk 
categorization systems (such as the CiPA 28-drug system 
and the JiCSA 60-drug system) proposed under Principle 
1, the number of drugs with consensus TdP risk can be 
significantly increased in the future, resulting in a much 
bigger development data set. The challenge of determining 
the number of additional drugs needed and setting the cri-
teria to select these drugs warrant a public and transparent 
process to reach consensus.
2. To develop better ways to capture the heterogenous drug re-
sponse in the population. Population modeling approaches 
have shown promise in simulating intersubject variability in 
both general and specific populations, and suggesting which 
individuals are most at risk of developing proarrhythmia after 
drug treatment.39,59,76 However, there may be a need to de-
velop novel methods to capture the covariance of individual 
physiological parameters and to integrate the quantification 
of uncertainty of pharmacological effects with the intersubject 
variability.
The goal of establishing the principles is to provide a discussion 
of the baseline guidance for the evaluation of individual proarrhyth-
mia models. Although these principles were illustrated through 
a few selected examples (especially the CiPAORdv1.0 model), 
they can be generally applied to any existing or newly developed 
proarrhythmia risk prediction models for performance assessment. 
While these principles could help stakeholders (regulatory agen-
cies or pharmaceutical industry) to assess whether a particular risk 
prediction model could be integrated into their decision-making 
process, they are not intended to establish specific criteria or give 
prescriptive guidance. Nor are these principles comprehensive, 
as some basic principles that are important for any scientific dis-
cipline, such as the development of proper Quality Control and/
or Quality Assurance procedures, are left out due to the difficulty 
in discussing such a complex subject across disciplines (in silico, in 
vitro, and in vivo/ex vivo models). Instead the objective is to stim-
ulate the formation of a harmonized foundation and conceptual 
framework for collecting useful information necessary to improve, 
judge, and compare various models for TdP risk prediction. The 
primary focus of the described example is evaluating the acceptance 
of in silico models for TdP risk prediction under the CiPA para-
digm, but because of their generic nature, these principles could be 
generally applied to any nonclinical models proposed to be used 
for proarrhythmia risk assessment. Importantly, models that are de-
veloped following these principles will still be combined with other 
relevant nonclinical and clinical information for an integrative and 
comprehensive risk assessment.
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